Activated protein C action in inflammation

British Journal of Haematology

Volumn 148, Issue 6, 2010, Pages 817-833

  Sarangi, Pranita P ^a   Lee, Hyun Wook ^a   Kim, Minsoo ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Activated protein C; Anticoagulation; Cytoprotection; Protein C; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5A; DROTRECOGIN; PLACEBO; PROTEIN C;

ANTICOAGULATION; APOPTOSIS; CELL MIGRATION; CELL PROTECTION; DRUG EFFECT; DRUG STRUCTURE; FIBRINOLYSIS; HOMEOSTASIS; HUMAN; INFECTION; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD CLOTTING; CHEMISTRY; GENETICS; METABOLISM; MUTAGENESIS; PHYSIOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

BLOOD COAGULATION; CYTOPROTECTION; HUMANS; INFLAMMATION; MUTAGENESIS; PROTEIN C; SEPSIS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649224137     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08020.x     Document Type: Review

References (132)

1. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., Beale, R., Svoboda, P., Laterre, P.F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Artigas, A., Percell, S.R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J.C. Creasey, A.A. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Journal of the American Medical Association, 290, 238 247.
2. Abraham, E., Laterre, P.F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B.L., Francois, B., Guy, J.S., Bruckmann, M., Rea-Neto, A., Rossaint, R., Perrotin, D., Sablotzki, A., Arkins, N., Utterback, B.G. Macias, W.L. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine, 353, 1332 1341. (Pubitemid 41362701)
3. Aoki, T., Suzuki, Y., Nishio, K., Suzuki, K., Miyata, A., Iigou, Y., Serizawa, H., Tsumura, H., Ishimura, Y., Suematsu, M. Yamaguchi, K. (1997) Role of CD18-ICAM-1 in the entrapment of stimulated leukocytes in alveolar capillaries of perfused rat lungs. American Journal of Physiology, 273, H2361 H2371.
4. Bae, J.S. Rezaie, A.R. (2009) Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thrombosis and Haemostasis, 101, 513 520.
5. Bae, J.S., Yang, L. Rezaie, A.R. (2007a) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 2867 2872.
6. Bae, J.S., Yang, L., Manithody, C. Rezaie, A.R. (2007b) Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. Journal of Biological Chemistry, 282, 9251 9259.
7. Barton, P., Kalil, A.C., Nadel, S., Goldstein, B., Okhuysen-Cawley, R., Brilli, R.J., Takano, J.S., Martin, L.D., Quint, P., Yeh, T.S., Dalton, H.J., Gessouron, M.R., Brown, K.E., Betts, H., Levin, M., Macias, W.L., Small, D.S., Wyss, V.L., Bates, B.M., Utterback, B.G. Giroir, B.P. (2004) Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics, 113, 7 17.
8. Berg, D.T., Gerlitz, B., Shang, J., Smith, T., Santa, P., Richardson, M.A., Kurz, K.D., Grinnell, B.W., Mace, K. Jones, B.E. (2003) Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proceedings of the National Academy of Sciences of the United States of America, 100, 4423 4428.
9. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W. Fisher, Jr., C.J. (2001a) Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine, 344, 699 709.
10. Bernard, G.R., Ely, E.W., Wright, T.J., Fraiz, J., Stasek, Jr., J.E., Russell, J.A., Mayers, I., Rosenfeld, B.A., Morris, P.E., Yan, S.B. Helterbrand, J.D. (2001b) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Critical Care Medicine, 29, 2051 2059.
11. de Boer, J.P., Wolbink, G.J., Thijs, L.G., Baars, J.W., Wagstaff, J. Hack, C.E. (1992) Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology, 24, 135 148.
12. Bogatcheva, N.V., Garcia, J.G. Verin, A.D. (2002) Molecular mechanisms of thrombin-induced endothelial cell permeability. Biochemistry (Moscow), 67, 75 84.
13. Brueckmann, M., Horn, S., Lang, S., Fukudome, K., Schulze Nahrup, A., Hoffmann, U., Kaden, J.J., Borggrefe, M., Haase, K.K. Huhle, G. (2005) Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thrombosis and Haemostasis, 93, 743 750.
14. Buisson-Legendre, N., Smith, S., March, L. Jackson, C. (2004) Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis and Rheumatism, 50, 2151 2156.
15. Burmeister, W.P., Gastinel, L.N., Simister, N.E., Blum, M.L. Bjorkman, P.J. (1994) Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature, 372, 336 343.
16. Chang, J.W., Mechling, D.E., Bachinger, H.P. Burrows, G.G. (2001) Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2. Journal of Biological Chemistry, 276, 24170 24176.
17. Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., Fukudome, K. Zlokovic, B.V. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Medicine, 9, 338 342.
18. Cheng, T., Petraglia, A.L., Li, Z., Thiyagarajan, M., Zhong, Z., Wu, Z., Liu, D., Maggirwar, S.B., Deane, R., Fernandez, J.A., LaRue, B., Griffin, J.H., Chopp, M. Zlokovic, B.V. (2006) Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nature Medicine, 12, 1278 1285.
19. Christiansen, W.T., Tulinsky, A. Castellino, F.J. (1994) Functions of individual gamma-carboxyglutamic acid (Gla) residues of human protein c. Determination of functionally nonessential Gla residues and correlations with their mode of binding to calcium. Biochemistry, 33, 14993 15000.
20. Coalson, J.J., Benjamin, B., Archer, L.T., Beller, B., Gilliam, C.L., Taylor, F.B. Hinshaw, L.B. (1978) Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circulatory shock, 5, 423 437.
21. Coughlin, S.R. (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. Journal of Thrombosis and Haemostasis, 3, 1800 1814.
22. Cunningham, M.A., Romas, P., Hutchinson, P., Holdsworth, S.R. Tipping, P.G. (1999) Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood, 94, 3413 3420.
23. Dahlback, B. Villoutreix, B.O. (2005) Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1311 1320.
24. Dhainaut, J.F., Yan, S.B., Margolis, B.D., Lorente, J.A., Russell, J.A., Freebairn, R.C., Spapen, H.D., Riess, H., Basson, B., Johnson, 3rd., G. Kinasewitz, G.T. (2003) Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thrombosis and Haemostasis, 90, 642 653.
25. Dhainaut, J.F., Antonelli, M., Wright, P., Desachy, A., Reignier, J., Lavoue, S., Charpentier, J., Belger, M., Cobas-Meyer, M., Maier, C., Mignini, M.A. Janes, J. (2009) Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Medicine, 35, 1187 1195.
26. Dittman, W. (1991) Thrombomodulin: biology and potential cardiovascular applications. Trends in Cardiovascular Medicine, 1, 331 336.
27. Doerschuk, C.M., Winn, R.K., Coxson, H.O. Harlan, J.M. (1990) CD18-dependent and -independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits. Journal of Immunology, 144, 2327 2333.
28. Doerschuk, C.M., Mizgerd, J.P., Kubo, H., Qin, L. Kumasaka, T. (1999) Adhesion molecules and cellular biomechanical changes in acute lung injury: Giles F. Filley Lecture. Chest, 116, 37S 43S.
29. Elphick, G.F., Sarangi, P.P., Hyun, Y.M., Hollenbaugh, J.A., Ayala, A., Biffl, W.L., Chung, H.L., Rezaie, A.R., McGrath, J.L., Topham, D.J., Reichner, J.S. Kim, M. (2009) Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood, 113, 4078 4085.
30. Esmon, C.T. (2005) The interactions between inflammation and coagulation. British Journal of Haematology, 131, 417 430.
31. Feistritzer, C. Riewald, M. (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood, 105, 3178 3184.
32. Feistritzer, C., Schuepbach, R.A., Mosnier, L.O., Bush, L.A., Di Cera, E., Griffin, J.H. Riewald, M. (2006) Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. Journal of Biological Chemistry, 281, 20077 20084.
33. Fernandez, J.A., Xu, X., Liu, D., Zlokovic, B.V. Griffin, J.H. (2003) Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells, Molecules, and Diseases, 30, 271 276.
34. Finigan, J.H., Dudek, S.M., Singleton, P.A., Chiang, E.T., Jacobson, J.R., Camp, S.M., Ye, S.Q. Garcia, J.G. (2005) Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. Journal of Biological Chemistry, 280, 17286 17293.
35. Fisher, Jr., C.J. Yan, S.B. (2000) Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Critical Care Medicine, 28, S49 S56.
36. Foster, D. Davie, E.W. (1984) Characterization of a cDNA coding for human protein C. Proceedings of the National Academy of Sciences of the United States of America, 81, 4766 4770.
37. Franscini, N., Bachli, E.B., Blau, N., Leikauf, M.S., Schaffner, A. Schoedon, G. (2004) Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation, 110, 2903 2909.
38. Friedrich, U., Blom, A.M., Dahlback, B. Villoutreix, B.O. (2001) Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. Journal of Biological Chemistry, 276, 24122 24128.
39. Fukudome, K. Esmon, C.T. (1994) Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. Journal of Biological Chemistry, 269, 26486 26491. (Pubitemid 24328474)
40. Gale, A.J., Sun, X., Heeb, M.J. Griffin, J.H. (1997) Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Science, 6, 132 140.
41. Gale, A.J., Tsavaler, A. Griffin, J.H. (2002) Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. Journal of Biological Chemistry, 277, 28836 28840.
42. Glasscock, L.N., Gerlitz, B., Cooper, S.T., Grinnell, B.W. Church, F.C. (2003) Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha(1)-antitrypsin. Biochimica et Biophysica Acta, 1649, 106 117.
43. Grinnell, B.W., Walls, J.D. Gerlitz, B. (1991) Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. Journal of Biological Chemistry, 266, 9778 9785.
44. Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H. Zlokovic, B.V. (2004) Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron, 41, 563 572.
45. Han, M.H., Hwang, S.I., Roy, D.B., Lundgren, D.H., Price, J.V., Ousman, S.S., Fernald, G.H., Gerlitz, B., Robinson, W.H., Baranzini, S.E., Grinnell, B.W., Raine, C.S., Sobel, R.A., Han, D.K. Steinman, L. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature, 451, 1076 1081.
46. He, X. Rezaie, A.R. (1999) Identification and characterization of the sodium-binding site of activated protein C. Journal of Biological Chemistry, 274, 4970 4976.
47. Humphries, M.J. (2000) Integrin structure. Biochemical Society Transactions, 28, 311 339.
48. Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69, 11 25.
49. Isermann, B., Vinnikov, I.A., Madhusudhan, T., Herzog, S., Kashif, M., Blautzik, J., Corat, M.A., Zeier, M., Blessing, E., Oh, J., Gerlitz, B., Berg, D.T., Grinnell, B.W., Chavakis, T., Esmon, C.T., Weiler, H., Bierhaus, A. Nawroth, P.P. (2007) Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nature Medicine, 13, 1349 1358.
50. Jhingan, A., Zhang, L., Christiansen, W.T. Castellino, F.J. (1994) The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma. Biochemistry, 33, 1869 1875.
51. Kerlin, B.A., Yan, S.B., Isermann, B.H., Brandt, J.T., Sood, R., Basson, B.R., Joyce, D.E., Weiler, H. Dhainaut, J.F. (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood, 102, 3085 3092.
52. Kerschen, E.J., Fernandez, J.A., Cooley, B.C., Yang, X.V., Sood, R., Mosnier, L.O., Castellino, F.J., Mackman, N., Griffin, J.H. Weiler, H. (2007) Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. Journal of Experimental Medicine, 204, 2439 2448.
53. Knobe, K.E., Berntsdotter, A., Shen, L., Morser, J., Dahlback, B. Villoutreix, B.O. (1999) Probing the activation of protein C by the thrombin-thrombomodulin complex using structural analysis, site-directed mutagenesis, and computer modeling. Proteins, 35, 218 234.
54. Kurosawa, S., Stearns-Kurosawa, D.J., Hidari, N. Esmon, C.T. (1997) Identification of functional endothelial protein C receptor in human plasma. Journal of Clinical Investigation, 100, 411 418.
55. Kurosawa, S., Esmon, C.T. Stearns-Kurosawa, D.J. (2000) The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. Journal of Immunology, 165, 4697 4703.
56. Levi, M. (2008) Activated protein C in sepsis: a critical review. Current Opinion in Hematology, 15, 481 486.
57. Levi, M., Levy, M., Williams, M.D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F.V., Wang, D., Sundin, D.P. Macias, W.L. (2007) Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). American Journal of Respiratory and Critical Care Medicine, 176, 483 490. (Pubitemid 47358102)
58. Liaw, P.C., Esmon, C.T., Kahnamoui, K., Schmidt, S., Kahnamoui, S., Ferrell, G., Beaudin, S., Julian, J.A., Weitz, J.I., Crowther, M., Loeb, M. Cook, D. (2004) Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood, 104, 3958 3964.
59. Liu, D., Cheng, T., Guo, H., Fernandez, J.A., Griffin, J.H., Song, X. Zlokovic, B.V. (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nature Medicine, 10, 1379 1383.
60. Liu, K.D., Levitt, J., Zhuo, H., Kallet, R.H., Brady, S., Steingrub, J., Tidswell, M., Siegel, M.D., Soto, G., Peterson, M.W., Chesnutt, M.S., Phillips, C., Weinacker, A., Thompson, B.T., Eisner, M.D. Matthay, M.A. (2008) Randomized clinical trial of activated protein C for the treatment of acute lung injury. American Journal of Respiratory and Critical Care Medicine, 178, 618 623.
61. Lo, S.K., Everitt, J., Gu, J. Malik, A.B. (1992) Tumor necrosis factor mediates experimental pulmonary edema by ICAM-1 and CD18-dependent mechanisms. Journal of Clinical Investigation, 89, 981 988.
62. Lust, M., Vulcano, M. Danese, S. (2008) The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation. Trends in Molecular Medicine, 14, 237 244.
63. Malik, A.B. Lo, S.K. (1996) Vascular endothelial adhesion molecules and tissue inflammation. Pharmacological Reviews, 48, 213 229.
64. Marti-Carvajal, A., Salanti, G. Cardona, A.F. (2008) Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews, 2008, CD004388.
65. Mather, T., Oganessyan, V., Hof, P., Huber, R., Foundling, S., Esmon, C. Bode, W. (1996) The 2.8 A crystal structure of Gla-domainless activated protein C. EMBO Journal, 15, 6822 6831.
66. Mosnier, L.O. Griffin, J.H. (2003) Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochemical Journal, 373, 65 70.
67. Mosnier, L.O., Zlokovic, B.V. Griffin, J.H. (2007a) The cytoprotective protein C pathway. Blood, 109, 3161 3172.
68. Mosnier, L.O., Yang, X.V. Griffin, J.H. (2007b) Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. Journal of Biological Chemistry, 282, 33022 33033.
69. Mosnier, L.O., Zampolli, A., Kerschen, E.J., Schuepbach, R.A., Banerjee, Y., Fernandez, J.A., Yang, X.V., Riewald, M., Weiler, H., Ruggeri, Z.M. Griffin, J.H. (2009) Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood, 113, 5970 5978.
70. Nadel, S., Goldstein, B., Williams, M.D., Dalton, H., Peters, M., Macias, W.L., Abd-Allah, S.A., Levy, H., Angle, R., Wang, D., Sundin, D.P. Giroir, B. (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet, 369, 836 843.
71. Nathan, C. (2006) Neutrophils and immunity: challenges and opportunities. Nature Reviews. Immunology, 6, 173 182.
72. Neyrinck, A.P., Liu, K.D., Howard, J.P. Matthay, M.A. (2009) Protective mechanisms of activated protein C in severe inflammatory disorders. British Journal of Pharmacology, 158, 1034 1047.
73. Nick, J.A., Coldren, C.D., Geraci, M.W., Poch, K.R., Fouty, B.W., O'Brien, J., Gruber, M., Zarini, S., Murphy, R.C., Kuhn, K., Richter, D., Kast, K.R. Abraham, E. (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood, 104, 3878 3885.
74. Oganesyan, V., Oganesyan, N., Terzyan, S., Qu, D., Dauter, Z., Esmon, N.L. Esmon, C.T. (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. Journal of Biological Chemistry, 277, 24851 24854.
75. Ohlin, A.K., Landes, G., Bourdon, P., Oppenheimer, C., Wydro, R. Stenflo, J. (1988) Beta-hydroxyaspartic acid in the first epidermal growth factor-like domain of protein C. Its role in Ca2+ binding and biological activity. Journal of Biological Chemistry, 263, 19240 19248.
76. Okajima, K. (2001) Regulation of inflammatory responses by natural anticoagulants. Immunological Reviews, 184, 258 274.
77. Pawlinski, R., Pedersen, B., Schabbauer, G., Tencati, M., Holscher, T., Boisvert, W., Andrade-Gordon, P., Frank, R.D. Mackman, N. (2004) Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood, 103, 1342 1347.
78. Perez-Casal, M., Downey, C., Cutillas-Moreno, B., Zuzel, M., Fukudome, K. Toh, C.H. (2009) Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects. Haematologica, 94, 387 394.
79. Preston, R.J., Ajzner, E., Razzari, C., Karageorgi, S., Dua, S., Dahlback, B. Lane, D.A. (2006) Multifunctional specificity of the protein C/activated protein C Gla domain. Journal of Biological Chemistry, 281, 28850 28857.
80. Ramamoorthy, C., Sasaki, S.S., Su, D.L., Sharar, S.R., Harlan, J.M. Winn, R.K. (1997) CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary E. coli, but not after S. aureus. Journal of Leukocyte Biology, 61, 167 172.
81. Regan, L.M., Mollica, J.S., Rezaie, A.R. Esmon, C.T. (1997) The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. Journal of Biological Chemistry, 272, 26279 26284.
82. Rezaie, A.R. (1996) Role of residue 99 at the S2 subsite of factor Xa and activated protein C in enzyme specificity. Journal of Biological Chemistry, 271, 23807 23814.
83. Rezaie, A.R. Esmon, C.T. (1992) The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. Journal of Biological Chemistry, 267, 26104 26109.
84. Rezaie, A.R. Esmon, C.T. (1993) Conversion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. Journal of Biological Chemistry, 268, 19943 19948.
85. Rezaie, A.R. Esmon, C.T. (1994) Proline at the P2 position in protein C is important for calcium-mediated regulation of protein C activation and secretion. Blood, 83, 2526 2531.
86. Rezaie, A.R., Mather, T., Sussman, F. Esmon, C.T. (1994) Mutation of Glu-80->Lys results in a protein C mutant that no longer requires Ca2+ for rapid activation by the thrombin-thrombomodulin complex. Journal of Biological Chemistry, 269, 3151 3154.
87. Riewald, M. Ruf, W. (2005) Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. Journal of Biological Chemistry, 280, 19808 19814.
88. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296, 1880 1882.
89. Riewald, M., Petrovan, R.J., Donner, A. Ruf, W. (2003) Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. Journal of Endotoxin Research, 9, 317 321.
90. Rittirsch, D., Flierl, M.A. Ward, P.A. (2008) Harmful molecular mechanisms in sepsis. Nature Reviews. Immunology, 8, 776 787.
91. Rivard, G.E., David, M., Farrell, C. Schwarz, H.P. (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. Journal of Pediatrics, 126, 646 652.
92. Roback, M.G., Stack, A.M., Thompson, C., Brugnara, C., Schwarz, H.P. Saladino, R.A. (1998) Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock, 9, 138 142.
93. Robriquet, L., Collet, F., Tournoys, A., Prangere, T., Neviere, R., Fourrier, F. Guery, B.P. (2006) Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respiratory Research, 7, 41.
94. Saposnik, B., Lesteven, E., Lokajczyk, A., Esmon, C.T., Aiach, M. Gandrille, S. (2008) Alternative mRNA is favored by the A3 haplotype of the EPCR gene PROCR and generates a novel soluble form of EPCR in plasma. Blood, 111, 3442 3451.
95. Schneppenheim, R. Greiner, J. (2006) Thrombosis in infants and children. Hematology American Society of Hematology. Education Program, 2006, 86 96.
96. Schuepbach, R.A., Feistritzer, C., Brass, L.F. Riewald, M. (2008) Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood, 111, 2667 2673.
97. Shen, L., Shah, A.M., Dahlback, B. Nelsestuen, G.L. (1997) Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10. Biochemistry, 36, 16025 16031.
98. Shen, L., Villoutreix, B.O. Dahlback, B. (1999) Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity. Thrombosis and Haemostasis, 82, 1078 1087.
99. Shua, F., Kobayashia, H., Fukudomeb, K., Tsuneyoshib, N., Kimotob, M. Teraoa, T. (2000) Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Letters, 477, 208 212.
100. Singleton, P.A., Dudek, S.M., Chiang, E.T. Garcia, J.G. (2005) Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB Journal, 19, 1646 1656.
101. Smirnov, M.D., Safa, O., Regan, L., Mather, T., Stearns-Kurosawa, D.J., Kurosawa, S., Rezaie, A.R., Esmon, N.L. Esmon, C.T. (1998) A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. Journal of Biological Chemistry, 273, 9031 9040.
102. Springer, T.A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 76, 301 314.
103. Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J.S., Ferrell, G.L. Esmon, C.T. (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the United States of America, 93, 10212 10216. (Pubitemid 26314601)
104. Sturn, D.H., Kaneider, N.C., Feistritzer, C., Djanani, A., Fukudome, K. Wiedermann, C.J. (2003) Expression and function of the endothelial protein C receptor in human neutrophils. Blood, 102, 1499 1505.
105. Sun, Y.H., Shen, L. Dahlback, B. (2003) Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. Blood, 101, 2277 2284.
106. Taylor, Jr., F.B., Chang, A., Hinshaw, L.B., Esmon, C.T., Archer, L.T. Beller, B.K. (1984) A model for thrombin protection against endotoxin. Thrombosis Research, 36, 177 185.
107. Taylor, Jr., F.B., Chang, A., Esmon, C.T., D'Angelo, A., Vigano-D'Angelo, S. Blick, K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. Journal of Clinical Investigation, 79, 918 925.
108. Taylor, Jr., F.B., Chang, A.C., Peer, G.T., Mather, T., Blick, K., Catlett, R., Lockhart, M.S. Esmon, C.T. (1991) DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood, 78, 364 368.
109. Toltl, L.J., Beaudin, S. Liaw, P.C. (2008) Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. Journal of Immunology, 181, 2165 2173.
110. Vermeer, C. (1990) Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochemical Journal, 266, 625 636.
111. Villegas-Mendez, A., Montes, R., Ambrose, L.R., Warrens, A.N., Laffan, M. Lane, D.A. (2007) Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3. Journal of Thrombosis and Haemostasis, 5, 980 988. (Pubitemid 46691727)
112. Vincent, J.L., Bernard, G.R., Beale, R., Doig, C., Putensen, C., Dhainaut, J.F., Artigas, A., Fumagalli, R., Macias, W., Wright, T., Wong, K., Sundin, D.P., Turlo, M.A. Janes, J. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Critical Care Medicine, 33, 2266 2277.
113. Ware, L.B. Matthay, M.A. (2000) The acute respiratory distress syndrome. New England Journal of Medicine, 342, 1334 1349.
114. Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., Knaub, S., Keinecke, H.O., Heinrichs, H., Schindel, F., Juers, M., Bone, R.C. Opal, S.M. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Journal of the American Medical Association, 286, 1869 1878.
115. Watanabe, S., Mukaida, N., Ikeda, N., Akiyama, M., Harada, A., Nakanishi, I., Nariuchi, H., Watanabe, Y. Matsushima, K. (1995) Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF. International Immunology, 7, 1037 1046.
116. White, B., Livingstone, W., Murphy, C., Hodgson, A., Rafferty, M. Smith, O.P. (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood, 96, 3719 3724.
117. White, T.C., Berny, M.A., Tucker, E.I., Urbanus, R.T., de Groot, P.G., Fernandez, J.A., Griffin, J.H., Gruber, A. McCarty, O.J. (2008) Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. Journal of Thrombosis and Haemostasis, 6, 995 1002.
118. Xiong, J.P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S.L. Arnaout, M.A. (2002) Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science, 296, 151 155.
119. Xu, J., Esmon, N.L. Esmon, C.T. (1999) Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. Journal of Biological Chemistry, 274, 6704 6710.
120. Yang, L., Manithody, C. Rezaie, A.R. (2002) Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C. Biochemistry, 41, 6149 6157.
121. Yang, L., Prasad, S., Di Cera, E. Rezaie, A.R. (2004) The conformation of the activation peptide of protein C is influenced by Ca2+ and Na+ binding. Journal of Biological Chemistry, 279, 38519 38524.
122. Yang, L., Manithody, C. Rezaie, A.R. (2005) The functional significance of the autolysis loop in protein C and activated protein C. Thrombosis and Haemostasis, 94, 60 68.
123. Yang, L., Bae, J.S., Manithody, C. Rezaie, A.R. (2007) Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. Journal of Biological Chemistry, 282, 25493 25500.
124. Yang, X.V., Banerjee, Y., Fernandez, J.A., Deguchi, H., Xu, X., Mosnier, L.O., Urbanus, R.T., de Groot, P.G., White-Adams, T.C., McCarty, O.J. Griffin, J.H. (2009) Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 274 279.
125. Yu, S., Zhang, L., Jhingan, A., Christiansen, W.T. Castellino, F.J. (1994) Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX. Biochemistry, 33, 823 831.
126. Yuda, H., Adachi, Y., Taguchi, O., Gabazza, E.C., Hataji, O., Fujimoto, H., Tamaki, S., Nishikubo, K., Fukudome, K., D'Alessandro-Gabazza, C.N., Maruyama, J., Izumizaki, M., Iwase, M., Homma, I., Inoue, R., Kamada, H., Hayashi, T., Kasper, M., Lambrecht, B.N., Barnes, P.J. Suzuki, K. (2004) Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood, 103, 2196 2204.
127. Yuksel, M., Okajima, K., Uchiba, M., Horiuchi, S. Okabe, H. (2002) Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thrombosis and Haemostasis, 88, 267 273.
128. Zhang, L. Castellino, F.J. (1990) A gamma-carboxyglutamic acid (gamma) variant (gamma 6D, gamma 7D) of human activated protein C displays greatly reduced activity as an anticoagulant. Biochemistry, 29, 10828 10834.
129. Zhang, L. Castellino, F.J. (1991) Role of the hexapeptide disulfide loop present in the gamma-carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C. Biochemistry, 30, 6696 6704.
130. Zhang, L. Castellino, F.J. (1994) The binding energy of human coagulation protein C to acidic phospholipid vesicles contains a major contribution from leucine 5 in the gamma-carboxyglutamic acid domain. Journal of Biological Chemistry, 269, 3590 3595.
131. Zhang, L., Jhingan, A. Castellino, F.J. (1992) Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood, 80, 942 952.
132. Zhong, Z., Ilieva, H., Hallagan, L., Bell, R., Singh, I., Paquette, N., Thiyagarajan, M., Deane, R., Fernandez, J.A., Lane, S., Zlokovic, A.B., Liu, T., Griffin, J.H., Chow, N., Castellino, F.J., Stojanovic, K., Cleveland, D.W. Zlokovic, B.V. (2009) Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. Journal of Clinical Investigation, 119, 3437 3449.